PL234888B1 - Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej - Google Patents

Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej Download PDF

Info

Publication number
PL234888B1
PL234888B1 PL401936A PL40193612A PL234888B1 PL 234888 B1 PL234888 B1 PL 234888B1 PL 401936 A PL401936 A PL 401936A PL 40193612 A PL40193612 A PL 40193612A PL 234888 B1 PL234888 B1 PL 234888B1
Authority
PL
Poland
Prior art keywords
ppi
mal
iii
cells
dendrimer
Prior art date
Application number
PL401936A
Other languages
English (en)
Polish (pl)
Other versions
PL401936A1 (pl
Inventor
Ida FRANIAK-PIETRYGA
Ida Franiak-Pietryga
Maria BRYSZEWSKA
Maria Bryszewska
Dietmar Appelhans
Barbara KLAJNERT
Barbara Klajnert
Original Assignee
Univ Lodzki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Lodzki filed Critical Univ Lodzki
Priority to PL401936A priority Critical patent/PL234888B1/pl
Priority to PCT/PL2013/000163 priority patent/WO2014088435A1/en
Priority to KR1020157018094A priority patent/KR20150093216A/ko
Priority to AU2013356793A priority patent/AU2013356793A1/en
Priority to JP2015546419A priority patent/JP2016501261A/ja
Priority to CA2893973A priority patent/CA2893973A1/en
Priority to US14/650,521 priority patent/US9877985B2/en
Priority to EP13821004.2A priority patent/EP2928479A1/en
Publication of PL401936A1 publication Critical patent/PL401936A1/pl
Priority to IL239144A priority patent/IL239144A0/en
Priority to US15/846,143 priority patent/US10022395B2/en
Publication of PL234888B1 publication Critical patent/PL234888B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C08G83/004—After treatment of dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL401936A 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej PL234888B1 (pl)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL401936A PL234888B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
CA2893973A CA2893973A1 (en) 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii
KR1020157018094A KR20150093216A (ko) 2012-12-06 2013-12-06 말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-OS-Mal-III의 적용
AU2013356793A AU2013356793A1 (en) 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-Mal-III
JP2015546419A JP2016501261A (ja) 2012-12-06 2013-12-06 マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−OS−Mal−IIIの使用
PCT/PL2013/000163 WO2014088435A1 (en) 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii
US14/650,521 US9877985B2 (en) 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III
EP13821004.2A EP2928479A1 (en) 2012-12-06 2013-12-06 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii
IL239144A IL239144A0 (en) 2012-12-06 2015-06-02 Application of a fourth-generation polypropyleneamine dendrimer ppi–g4–os–mal–iii coated with maltotriose
US15/846,143 US10022395B2 (en) 2012-12-06 2017-12-18 Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL401936A PL234888B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Publications (2)

Publication Number Publication Date
PL401936A1 PL401936A1 (pl) 2014-06-09
PL234888B1 true PL234888B1 (pl) 2020-04-30

Family

ID=49955472

Family Applications (1)

Application Number Title Priority Date Filing Date
PL401936A PL234888B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Country Status (9)

Country Link
US (1) US9877985B2 (cg-RX-API-DMAC10.html)
EP (1) EP2928479A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016501261A (cg-RX-API-DMAC10.html)
KR (1) KR20150093216A (cg-RX-API-DMAC10.html)
AU (1) AU2013356793A1 (cg-RX-API-DMAC10.html)
CA (1) CA2893973A1 (cg-RX-API-DMAC10.html)
IL (1) IL239144A0 (cg-RX-API-DMAC10.html)
PL (1) PL234888B1 (cg-RX-API-DMAC10.html)
WO (1) WO2014088435A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL234887B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PL416636A1 (pl) * 2016-03-24 2017-09-25 Univ Łódzki Medyczne zastosowanie dendrymeru polipropylenoiminowego czwartej generacji, opłaszczonego maltotriozą

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208580A1 (en) 2005-09-19 2009-08-20 Regents Of The University Of Michigan Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
US20110177602A1 (en) * 2007-06-27 2011-07-21 Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG Composite Structure
PL234887B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Also Published As

Publication number Publication date
KR20150093216A (ko) 2015-08-17
AU2013356793A1 (en) 2015-07-23
CA2893973A1 (en) 2014-06-12
WO2014088435A1 (en) 2014-06-12
PL401936A1 (pl) 2014-06-09
US20150306134A1 (en) 2015-10-29
EP2928479A1 (en) 2015-10-14
US9877985B2 (en) 2018-01-30
JP2016501261A (ja) 2016-01-18
IL239144A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
Sun et al. Light-activated gold–selenium core–shell nanocomposites with NIR-II photoacoustic imaging performances for heart-targeted repair
Zhang et al. Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models
US20220347314A1 (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
Tian et al. Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery
Cosco et al. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer
Gorzkiewicz et al. Dendrimers as nanocarriers for nucleoside analogues
CN105287383A (zh) 新型米托蒽醌脂质体联合化疗药物在抗肿瘤治疗中的应用
JP2021512110A (ja) ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
Zhang et al. Hypoxia-triggered tumor specific glutamine inhibition for reversing cisplatin resistance of chemotherapy
US10925852B2 (en) Talc-bound compositions and uses thereof
KR19990036137A (ko) 암 성장을 억제하기 위한 그리세오풀빈의 용도
WO2019073296A1 (en) LIPOSOMAL FORMULATIONS OF BISANTRENE OR DERIVATIVES OR THE LIKE THEREOF
EP2825198B1 (en) Glut-1 targeted and curcumin loaded micelles
PL234887B1 (pl) Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
US9877985B2 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III
JP7454263B2 (ja) 高分子薬剤
Dohadwala et al. Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm
CN1046464A (zh) 减少药物副效应的方法
WO2017163124A2 (en) Medical use of poly(propylene imine) glycodendrimers
PL238795B1 (pl) Ekstrakt z grzyba poliporoidalnego, kompozycja zawierająca taki ekstrakt oraz jego zastosowanie
PL241754B1 (pl) Sposób wytwarzania układu zawierającego nanocząstki złota oraz wytworzony tym sposobem układ zawierający nanocząstki złota do zastosowania w terapii przeciwnowotworowej
EP4450092A1 (en) Modified oligonucleotide-drug conjugate and use thereof
RU2372073C1 (ru) Доставка гетероциклических антибиотиков к раковым клеткам с помощью нанонуклеотидных фармакосом
Tannous The combination of Gadolinium-based nanoparticles, radiotherapy and immune checkpoint inhibitors: a novel therapeutic opportunity for cancer treatment
Jayawardhana Development of Photoactivatable Platinum Therapeutics to Eradicate Ovarian Cancer Stem Cells